{"slug":"vip-muscle-loss","verification":{"valid":true,"entries":2,"head":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"},"energy":{"passes":2,"tokens_in":14739,"tokens_out":2818,"tokens_total":17557,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"},"provenance":[{"ts":"2026-06-29T22:28:05.298Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Vip for Muscle Loss\nSlug: vip-muscle-loss\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"vip\",\"name\":\"VIP\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"vip\",\"name\":\"VIP\",\"section_title\":\"Why VIP might help you\",\"layer\":\"immune / autonomic\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **VIP** → immune / autonomic\",\"section_headings\":[\"What's breaking down\",\"Why VIP might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight","response":"{\n  \"slug\": \"vip-muscle-loss\",\n  \"title\": \"VIP for Muscle Loss: Preclinical Signals on Vasoactive Intestinal Peptide\",\n  \"body\": \"## What's breaking down\\nMuscle loss, or atrophy, occurs when breakdown outruns repair in skeletal muscle tissue. Layers include disuse from reduced activity, age-related sarcopenia with declining anabolic signals, inflammation that promotes protein breakdown via pathways like MuRF1, and impaired blood flow or oxygenation that limits nutrient delivery and waste removal. In disuse or ischemia models, contractile force drops as muscle fibers shrink. VIP sits in the immune and autonomic layer because it modulates inflammation and smooth muscle tone in vessels, potentially supporting repair signals rather than suppressing symptoms directly.\\n\\n## Why VIP might help you\\nIf your muscle loss involves an immune or autonomic component, such as chronic low-grade inflammation accelerating protein breakdown or autonomic imbalance affecting blood flow, VIP is discussed for its studied effects on tissue repair pathways. Step one: VIP activates VPAC2 receptors, which in lab models reduced skeletal muscle mass loss during disuse. Step two: This receptor activation preserved force generation, pointing to a direct influence on muscle maintenance rather than masking fatigue. Step three: In reperfusion settings after ischemia, VIP raised contractile force and tissue oxygen levels above baseline in rat muscle. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain. If autonomic regulation of blood vessels limits delivery during recovery, VIP's vasodilatory actions could fit there too.\\n\\n## How these fit together\\nSingle-compound focus — VIP targets the immune/autonomic layer. If your profile includes other degeneration layers like mitochondrial decline or hormonal shifts, this peptide addresses only the immune/autonomic slice without overlapping other mechanisms.\\n\\n## What t","tokens_in":14739,"tokens_out":2818,"cost":0,"prev":"genesis","hash":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e"},{"ts":"2026-07-17T02:43:25.271Z","model":"owner","action":"voxel_divide","prompt":"","input":"vip-muscle-loss","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"51f30a41dda599e0554f83234ddc244f754f4b3203859afc044bff5cee47c01e","hash":"bf5b64df9799413c34643e9172e1586e7f01272be66e3a35710a6938096f8366"}]}